BenzingaDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 02:31:36·⟳ 抓取 02:31:41 +5s·⚡ 决策 10-22 02:32:55 +1m14s·6.0 天前
赛默飞世尔 Q3 双超预期并上调 FY2026 指引，Benzinga 盘中复读财报内容
本条 Benzinga 文章是今晨 Q3 财报（11:14 UTC）、上调指引社媒（11:18 UTC）、电话会收入指引（12:06 UTC）及盘中综述（17:59 UTC）之后的第 5 次同事件复读，无任何新增数字、指引修正或管理层表态。财报本身对约 $2571 亿超大市值仅为温和超预期（营收超约 1.6%、EPS 超约 4.4%），上调后指引中值基本贴齐一致预期；盘前一度下跌约 3.8% 后靠大盘回升至 +1.16%，已贴近 52 周高位、近 13 周累计上涨约 23%，做多无正期望；真实 beat+上调指引又不构成做空催化。
📄 原文Benzinga↗ 原文
Thermo Fisher Scientific Highlights Continued Strong Customer Activity
Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter adjusted earnings of $6.68 per share, beat…
不做 Thermo Fisher Scientific（TMO.US）
无增量事实的盘中复读（同一财报当日已第 5 次被处理）；约 $2571 亿超大市值温和超预期、指引中值基本持平一致预期，盘前见光下跌后仅随大盘回升 1.16%、贴近 52 周高位且近 13 周已涨约 23%，做多无正期望；真实 beat+上调指引不构成做空催化，多空均不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
同一份 Q3 财报已被本臂在盘前和盘中多次研判，本条为无增量的媒体复读；TMO 超大市值、温和超预期、指引中值仅持平预期且股价贴近 52 周高位，多空均无 edge，不做。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 high · price-in 风险 high ↗
主要风险
- 若电话会后续出现明显强于当前区间的指引上修或新上调周期表述，需重新评估右侧机会（本信号未提供）
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-21 · 影响 weakens
上调后 EPS 指引中值约 $25.28 仅微高于一致预期 $25.14，营收指引中值 $479.5 亿甚至低于一致预期 $478.85 亿的贴线水平，缺乏大预期差
检索:TMO FY2026 guidance raise vs consensus 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认不做；未据此外推新交易
方向:同一催化已在本臂当日多条同事件记录中完成研判，本条无增量事实，无需再引入外部先例
涨幅量级:不适用：消息为复读，价格反应已在当日盘前-盘中走完
形态:盘前利好出尽下跌约 3.8% 后随大盘回升，呈典型大市值温和 beat 见光反应
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,859 ms
{"result": "search_processed_events:agent query=`thermo fisher q3 2026 earnings beat raised guidance | tmo third quarter adjusted eps $6.68 sales $12.137 billion | 赛默飞 2026 三季报 上调全年指引`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26382 条本臂决策(完整)，返回 5 条候选。\n• 10-21 11:18 UTC(北京 19:18) [bm25:48%] 不做 TMO.US (tw - stock_quote 成功 stock_tools HTTP · 281 ms
{
原文全文
展开原文 · 2,767 字
Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter adjusted earnings of $6.68 per share, beating the street view of $6.40.
The life science giant’s quarterly sales of $12.137 billion increased 9% year-over-year, beating the analyst consensus estimate of $11.946 billion. Organic revenue growth was 6%.
Adjusted operating margin was 24.5%, compared with 23.3% a year ago.
Raised Fiscal 2026 Guidance And Market Demand
Thermo Fisher Scientific raised fiscal 2026 adjusted earnings guidance from $24.93-$25.33 per share to $25.13-$25.43 per share, compared to the consensus of $25.14.
The company also raised 2026 sales guidance from $47.4 billion-$48.10 billion to $47.70 billion-$48.20 billion vs $47.885 billion.
The company in its earnings call said that the improved end market conditions witnessed in the second quarter continued in the third quarter with strong customer activity.
Segment Breakdown
In Life Sciences Solutions, Q3 reported revenue increased 5% to $2.719 billion versus the prior-year quarter, and organic revenue growth was 1%. Growth in this segment was led by the bioproduction business.
During the quarter, in the Analytical Instruments segment, both reported revenue and organic revenue increased 6% to $2.00 billion, led by growth in the electron microscopy business, and there was also good growth in the chromatography and mass spectrometry business.
Specialty Diagnostics, in Q3, reported revenue declined 6% year over year to $1.098 billion and organic revenue was flat. Growth in this segment was led by our transplant diagnostics business.
In the Laboratory Products and Biopharma Services segment, reported revenue increased 15% to $6.863 billion, and organic revenue growth was 10%.
In Q3, the company said it delivered strong growth in the pharma services business, in the research and safety market channel, and also had strong growth in the clinical research business.
End Market Performance And Executive Insights
Chairman and CEO Marc Casper said the pharma and biotech business delivered high-single-digit growth during the quarter, led by the pharma services business and the research and safety market channel.
The company also reported growth in the clinical research business.
In academic and government, revenue was flat during the quarter; it saw good performance in the chromatography and mass spectrometry business.
TMO Price Action: Thermo Fisher Scientific shares were up 1.04% at $694.55 at the time of publication on Wednesday. The stock is trading near its 52-week high of $704.00, according to Benzinga Pro data.
Photo: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
The life science giant’s quarterly sales of $12.137 billion increased 9% year-over-year, beating the analyst consensus estimate of $11.946 billion. Organic revenue growth was 6%.
Adjusted operating margin was 24.5%, compared with 23.3% a year ago.
Raised Fiscal 2026 Guidance And Market Demand
Thermo Fisher Scientific raised fiscal 2026 adjusted earnings guidance from $24.93-$25.33 per share to $25.13-$25.43 per share, compared to the consensus of $25.14.
The company also raised 2026 sales guidance from $47.4 billion-$48.10 billion to $47.70 billion-$48.20 billion vs $47.885 billion.
The company in its earnings call said that the improved end market conditions witnessed in the second quarter continued in the third quarter with strong customer activity.
Segment Breakdown
In Life Sciences Solutions, Q3 reported revenue increased 5% to $2.719 billion versus the prior-year quarter, and organic revenue growth was 1%. Growth in this segment was led by the bioproduction business.
During the quarter, in the Analytical Instruments segment, both reported revenue and organic revenue increased 6% to $2.00 billion, led by growth in the electron microscopy business, and there was also good growth in the chromatography and mass spectrometry business.
Specialty Diagnostics, in Q3, reported revenue declined 6% year over year to $1.098 billion and organic revenue was flat. Growth in this segment was led by our transplant diagnostics business.
In the Laboratory Products and Biopharma Services segment, reported revenue increased 15% to $6.863 billion, and organic revenue growth was 10%.
In Q3, the company said it delivered strong growth in the pharma services business, in the research and safety market channel, and also had strong growth in the clinical research business.
End Market Performance And Executive Insights
Chairman and CEO Marc Casper said the pharma and biotech business delivered high-single-digit growth during the quarter, led by the pharma services business and the research and safety market channel.
The company also reported growth in the clinical research business.
In academic and government, revenue was flat during the quarter; it saw good performance in the chromatography and mass spectrometry business.
TMO Price Action: Thermo Fisher Scientific shares were up 1.04% at $694.55 at the time of publication on Wednesday. The stock is trading near its 52-week high of $704.00, according to Benzinga Pro data.
Photo: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
cfaffb58f6· 2026-10-22 02:32 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前